Ulrik Abildgaard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ulrik Abildgaard has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Christian Torp-Pedersen
Copenhagen University Hospital, Steno Diabetes Center Copenhagen Herlev Denmark
1 shared publication - Emil Loldrup Fosbøl
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital , Blegdamsvej 9, Copenhagen 2100
1 shared publication - Fredrik Folke
Research Department, Emergency Medical Services, Copenhagen University Hospital, Capital Region of Denmark, Copenhagen, Denmark
1 shared publication - Gunnar Hilmar Gislason
Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte , Hospitalsvej 1, 2900 Hellerup
1 shared publication - Henrik Enghusen Poulsen
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, København, Denmark
1 shared publication - Jan K Madsen
Department of Cardiology, Copenhagen University Hospital Gentofte, Niels Andersens Vej 65, 2900 Hellerup, Denmark
1 shared publication
Latest Publications
- Open Access
- 29 January 2010
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 10 (1) , 6
Duration of clopidogrel treatment and risk of mortality and recurrent myocardial infarction among 11 680 patients with myocardial infarction treated with percutaneous coronary intervention: a cohort study
The optimal duration of clopidogrel treatment after percutaneous coronary intervention (PCI) is unclear. We studied the risk of death or recurrent myocardial infarction (MI) in relation to 6- and 12-months clopidogrel treatment among MI patients treated with PCI. Using nationwide registers of hospitalizations and drug dispensing from pharmacies we identified 11 680 patients admitted with MI, treated with PCI and clopidogrel. Clopidogrel treatment was categorized in a 6-months and a 12-months regimen. Rates of death, recurrent MI or a combination of both were analyzed by the Kaplan Meier method and Cox proportional hazards models. Bleedings were compared between treatment regimens. The Kaplan Meier analysis indicated no benefit of the 12-months regimen compared with the 6-months in all endpoints. The Cox proportional hazards analysis confirmed these findings with hazard ratios for the 12-months regimen (the 6-months regimen used as reference) for the composite endpoint of 1.01 (confidence intervals 0.81-1.26) and 1.24 (confidence intervals 0.95-1.62) for Day 0-179 and Day 180-540 after discharge. Bleedings occurred in 3.5% and 4.1% of the patients in the 6-months and 12-months regimen (p = 0.06). We found comparable rates of death and recurrent MI in patients treated with 6- and 12-months' clopidogrel. The potential benefit of prolonged clopidogrel treatment in a real-life setting remains uncertain.
- 29 January 2010
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 10 (1) , 6
Open AccessDuration of clopidogrel treatment and risk of mortality and recurrent myocardial infarction among 11 680 patients with myocardial infarction treated with percutaneous coronary intervention: a cohort study
The optimal duration of clopidogrel treatment after percutaneous coronary intervention (PCI) is unclear. We studied the risk of death or recurrent myocardial infarction (MI) in relation to 6- and 12-months clopidogrel treatment among MI patients treated with PCI. Using nationwide registers of hospitalizations and drug dispensing from pharmacies we identified 11 680 patients admitted with MI, treated with PCI and clopidogrel. Clopidogrel treatment was categorized in a 6-months and a 12-months regimen. Rates of death, recurrent MI or a combination of both were analyzed by the Kaplan Meier method and Cox proportional hazards models. Bleedings were compared between treatment regimens. The Kaplan Meier analysis indicated no benefit of the 12-months regimen compared with the 6-months in all endpoints. The Cox proportional hazards analysis confirmed these findings with hazard ratios for the 12-months regimen (the 6-months regimen used as reference) for the composite endpoint of 1.01 (confidence intervals 0.81-1.26) and 1.24 (confidence intervals 0.95-1.62) for Day 0-179 and Day 180-540 after discharge. Bleedings occurred in 3.5% and 4.1% of the patients in the 6-months and 12-months regimen (p = 0.06). We found comparable rates of death and recurrent MI in patients treated with 6- and 12-months' clopidogrel. The potential benefit of prolonged clopidogrel treatment in a real-life setting remains uncertain.